Our Pipeline

We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to reduce the neuronal hyperexcitability that underlies debilitating brain conditions including epilepsy. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical meaning.

Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with epilepsies and neurological disorders that present with seizures.

	Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial
+	Soticlestat
	Cholesterol 24-hydroxylase inhibitor	Dravet syndrome
	Out-licensed to	Lennox-Gastaut syndrome
+	OV888 & ROCK2 Platform*
	Selective ROCK2 inhibitor Collaboration with	Brainstem cavernous malformations, undisclosed rare CNS indications
+	OV329
	GABA-aminotransferase inhibitor In-licensed from	Oral formulation for chronic treatment of epilepsies
	GABA-aminotransferase inhibitor In-licensed from	IV formulation for acute treatment of seizures
+	OV350 & KCC2 Platform
	KCC2 transporter activators In-licensed from	Resistant epilepsies and other neuropathologies

Drug	Indication	Stage
Soticlestat
Cholesterol 24-hydroxylase inhibitor	Dravet syndrome	Phase 3
Out-licensed to	Lennox-Gastaut syndrome	Phase 3
OV888 & ROCK2 Platform*
Selective ROCK2 inhibitor Collaboration with	Brainstem cavernous malformations, undisclosed rare CNS indications	Phase 1
OV329
GABA-aminotransferase inhibitor In-licensed from	Oral formulation for chronic treatment of epilepsies	Phase 1
GABA-aminotransferase inhibitor In-licensed from	IV formulation for acute treatment of seizures	Preclinical
OV350 & KCC2 Platform
KCC2 transporter activators In-licensed from	Resistant epilepsies and other neuropathologies	Preclinical

*Undisclosed ROCK2 inhibitor programs

Publications and Posters »